Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville

Lonza Group AG has finalized the acquisition of a large-scale biologics manufacturing site in Vacaville, California, from Roche for USD 1.2 billion. This site is one of the largest biologics facilities globally, extending Lonza's US footprint, particularly on the West Coast. The acquisition complements its existing network, which includes an East Coast site in Portsmouth and facilities in Europe and Asia Pacific.

The Vacaville site, with a bioreactor capacity of around 330,000 liters, enhances Lonza's capabilities for late-stage clinical and commercial products. The site will support the growing demand for commercial manufacturing and advance new molecules on their path to market. Over 750 employees from the site have now joined Lonza’s Biologics division.

Wolfgang Wienand, CEO of Lonza, remarked that the acquisition represents a significant milestone and will help deliver long-term value. Lonza plans to invest approximately CHF 500 million to upgrade the facility, ensuring it meets the demands for next-generation mammalian biologics therapies.